April 4, 2016

Verseon to present additional preclinical results at BioEurope Spring 2016 conference

Fremont, California - Verseon Corporation (AIM: VSN) announces today that the company will present new preclinical results based on a stasis-induced venous thrombosis model for several promising oral anticoagulant drug candidates on April 5th at the BioEurope Spring 2016 conference in Stockholm, Sweden. The data conclusively demonstrates the effectiveness of Verseon’s novel, highly selective direct thrombin inhibitors (DTIs) as a potential treatment for venous thrombotic disorders while maintaining a lower bleeding risk than current drugs.

The latest preclinical model adds to the list of successful studies performed by the company and broadens the therapeutic potential of Verseon’s DTIs to a wide range of thrombotic disorders, including stroke prevention for atrial fibrillation patients, deep vein thrombosis, pulmonary embolism, and acute coronary syndrome.

About Verseon’s Anticoagulant Program

Verseon’s new class of anticoagulants are part of a growing portfolio of drug programs being developed with the aid of the company’s proprietary, computational drug discovery platform. The novel small-molecule DTIs act through reversible covalent inhibition, a unique mode of action that leads to novel pharmacology, including lower bleeding liability as seen in multiple laboratory tests. In addition to efficacy and lower bleeding risk, Verseon’s new class of anticoagulants also has pharmacokinetic properties suitable for oral dosing.

About Verseon

Verseon is a technology-based pharmaceutical company that employs its proprietary computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. Verseon’s platform can consistently design novel drugs that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.

-Ends-

For further information please contact

Verseon Corporation +1 (510) 225 9000
Arthur Shmurun / Amy Thai

Financial and business media enquiries:

Abchurch Communications Limited +44 (0) 20 7398 7719
Jamie Hooper / Alex Shaw / Abbie Warner

Trade and pharma media enquiries:

Vane Percy Roberts +44 (0) 1737 821 890
Simon Vane Percy
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS
THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS, WHICH ARE GENERALLY STATEMENTS THAT ARE NOT HISTORICAL FACTS. FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE WORDS "EXPECTS," "ANTICIPATES," "BELIEVES," "INTENDS," "ESTIMATES," "PLANS," "WILL," “OUTLOOK” AND SIMILAR EXPRESSIONS. FORWARD-LOOKING STATEMENTS ARE BASED ON MANAGEMENT’S CURRENT PLANS, ESTIMATES, ASSUMPTIONS AND PROJECTIONS, AND SPEAK ONLY AS OF THE DATE THEY ARE MADE. WE UNDERTAKE NO OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENT IN LIGHT OF NEW INFORMATION OR FUTURE EVENTS, EXCEPT AS OTHERWISE REQUIRED BY LAW. FORWARD-LOOKING STATEMENTS INVOLVE INHERENT RISKS AND UNCERTAINTIES, MOST OF WHICH ARE DIFFICULT TO PREDICT AND ARE GENERALLY BEYOND OUR CONTROL. ACTUAL RESULTS OR OUTCOMES MAY DIFFER MATERIALLY FROM THOSE IMPLIED BY THE FORWARD-LOOKING STATEMENTS AS A RESULT OF THE IMPACT OF A NUMBER OF FACTORS.

Proprietary Platform

Consistently designs novel drug candidates that are unlikely to be found using conventional methods

 

Drug Programs

Three different therapeutic areas, all with unmet (or poorly met) medical needs